A Rare Investment Opportunity in Cancer Innovation

Alpha Tau Medical (NASDAQ: DRTS) may be one of the most overlooked opportunities in oncology today. Its core technology, Alpha DaRT, is a disruptive cancer therapy that’s already demonstrating real-world impact – and yet, the company’s current valuation barely reflects the clinical progress and infrastructure already in place.

A Groundbreaking Therapy, Already Delivering Results

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to destroy solid tumors by delivering localized alpha radiation directly inside them – without damaging surrounding healthy tissue.

The treatment is:

• Single-session

• Minimally invasive

• Free of major side effects

• Simple to administer

• Low-cost and scalable, with no need for complex equipment or hospital infrastructure

In early trials, 100% tumor response was observed across multiple cancers, including pancreatic, lung, skin, breast, prostate, and brain. In fact, Alpha DaRT has already been tested across dozens of tumor types, and showed effect in every single one.

Beyond local control, Alpha DaRT may also stimulate an immune response, creating the potential for systemic anti-cancer effects.

Infrastructure, Funding, and Regulatory Momentum

Alpha Tau isn’t just developing a concept. It’s executing a global plan:

• 2 manufacturing facilities already operational (Israel and USA)

• 3rd facility under construction in New Hampshire

• Over 50 clinical sites worldwide

• Multiple FDA-approved trials already underway — including for pancreatic cancer, brain tumors, and skin cancer

• Breakthrough Device Designation from the FDA

• Accepted into the FDA’s TAP program (Total Product Life Cycle Advisory Program) — a highly selective program that offers enhanced guidance and resources to help accelerate the development and review of breakthrough technologies

• Regulatory submission under review in Japan (PMDA)

• Approval for skin cancer treatment in Israel

• Ongoing collaboration with Merck’s Keytruda in pancreatic cancer

• $50M+ cash on hand, runway through 2026

• Preparing for commercialization

This is not a company just starting out — it's a company getting ready to scale.

Even One Indication Could Be Worth Billions

Let’s talk numbers.

🧠 Cutaneous Squamous Cell Carcinoma (cSCC)

• 1.8 million new cases per year in the U.S.

• Approximately 64,000 cases are advanced and not treatable effectively with current options.

• These are exactly the patients Alpha DaRT is designed to help.

At a treatment price of $50,000–$100,000: 64,000 patients × $50,000 = $3.2 billion annually 64,000 × $100,000 = $6.4 billion annually

From just one subset of one cancer, in one country.

🩺 Pancreatic Cancer

• 66,000 new cases annually (U.S.)

• Among the deadliest, with extremely limited options

• At $50,000–$100,000 per treatment: 66,000 × $50,000 = $3.3 billion/year 66,000 × $100,000 = $6.6 billion/year

Again — just one cancer, in just one country.

Multiply That by the World

Alpha DaRT has also shown results in:

• Skin cancer

• Breast cancer

• Lung cancer

• Liver metastases

• Prostate cancer

• Brain tumors ...and more.

The revenue projections above are U.S.-only — but cancer knows no borders. Alpha Tau is already running clinical trials and building infrastructure in multiple countries, with the goal of reaching patients worldwide. And unfortunately, the global numbers are even higher.

With a total addressable market easily surpassing $100 billion, and a treatment that’s efficient, scalable, and already showing efficacy — the upside is clear.

A Disconnect — And a Window of Opportunity

Despite all of this — the trials, the factories, the regulatory momentum — Alpha Tau is still trading at a valuation far below its peers. Companies at a similar stage, with fewer trials and less infrastructure, often trade at 5–10x higher valuations.

So why is Alpha Tau still under the radar?

Because until now, the company has maintained a low public profile. There’s been no aggressive marketing, minimal retail exposure, and a focus on clinical execution over promotion. But that’s starting to change — both inside and outside the company.

With major regulatory events on the horizon — including potential PMDA approval in Japan and continued FDA progress in the U.S. — and with more eyes now turning toward the company, this window of undervaluation may not last long.

Why This Matters Now

This isn’t a promise. It’s an observation: that few companies reach this level of readiness while still flying under the radar.

Alpha Tau has the science. It has the infrastructure. It has the financial runway. And it has a product that could save lives — and change cancer treatment forever.

For those who are paying attention — this may be one of the most compelling biotech opportunities in years.